Navigation Links
Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
Date:12/19/2007

ed through three intra-articular administrations of two milliliters each given at one-week intervals. Synvisc-One is delivered as three combined doses in just one single six milliliter administration. Competitive injection regimens call for up to five injections.

Safety and efficacy

Genzyme's regulatory filing for CE mark of Synvisc-One was based on final data from a prospective, randomized, double-blind, placebo-controlled study that involved 253 patients at 21 sites across Europe. In this study, a statistically significant improvement in pain from osteoarthritis of the knee was observed over 26 weeks when compared to pain relief for patients receiving placebo treatment.

Statistically significant differences in favor of Synvisc-One were also observed in several secondary outcome measures of efficacy, including patient and clinician global assessments. The safety profile of Synvisc-One was no different from that of placebo; also, there was no increased risk of post- injection adverse reactions in the patients receiving a second injection of Synvisc-One six months after the first injection.

Data from the study were presented earlier this year at the European League Against Rheumatism annual meeting in Barcelona, Spain and have been accepted for a podium presentation at the American Association of Orthopaedic Surgeons annual meeting in March, 2008.

"Synvisc-One provides long-term pain relief for patients without the systemic safety risks associated with traditional OA therapies such as NSAIDs and COX2 inhibitors," stated Xavier Chevalier M.D., Head of Rheumatology, Hopital Henri Mondor, Creteil France. "This is a unique opportunity for physicians to treat patients with a single injection viscosupplement that offers a very good risk-benefit profile."

About Synvisc

Synvisc is indicated for the treatment of pain due to osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonphar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Beach County, Florida (PRWEB) August 27, 2014 ... Company Inc. (SCI) is announcing the creation of ... priority is to take the SCI’s philosophy of ... the company’s research and development actions are based ... , This new Scientific Advisory Board provides a ...
(Date:8/27/2014)... August 27, 2014 Remcom announces an ... with new features for the biomedical industry. The ... Biological Thermal Sensor, exclusive to the Bio-Pro version of ... of XFdtd, developed to calculate the biological effects of ... been added to all versions to expand engineers’ post-processing ...
(Date:8/26/2014)...  NeuroSigma, Inc., a Los Angeles ... today announced that it has filed a registration statement ... Commission relating to a proposed initial public offering of ... offered and the price range for the proposed offering ... will act as the book-running manager for the proposed ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... Inc. (NYSE: HGR ) announced net sales of $192.3 million ... million, or 7.6%, from $178.7 million in the prior year. ... per diluted share compared to $0.23 per diluted share for the ... sales increase for the quarter ended September 30, 2009 was primarily ...
... (OTC Bulletin Board: OXBO) today announced the expansion of the ... members. Appointed to the company,s board were Rene A. Eckert ... company board now has eight members. , Bill Chatfield most ... Service System from November of 2004 to May of this ...
... Ph.D., J.D., will be giving opening, introductory and concluding ... and IP Professionals. This exciting conference brings together ... service providers, and will be held Wednesday, November 4, ... Hotel at the University of Cincinnati. , Based ...
Cached Biology Technology:Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 2Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 3Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 4Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 5Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 6Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 7Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 8Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 9Oxygen Biotherapeutics, Inc. Expands Board of Directors 2
(Date:8/27/2014)... fish began exploring land and evolved into tetrapods today,s ... fish used their fishy bodies and fins in a terrestrial ... mysteries. , Researchers at McGill University published in the ... Polypterus , to help show what might have happened ... Polypterus is an African fish that can breathe ...
(Date:8/27/2014)... frequently found in forests has created a thriving habitat ... a new University of Georgia study has found. , ... in the early 1900s, is one of the most ... a dozen states in the past century, particularly in ... it can survive in widely diverse ecosystems and has ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and ... Annual International Conference (EMBC,14), this year being held at ... Chicago, Illinois , from Tuesday, August 26 through ... and industry professionals in science, medicine, and engineering are ... This year,s conference theme is ...
Breaking Biology News(10 mins):Walking fish reveal how our ancestors evolved onto land 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3
... microorganisms, living together with human cells, usually in harmony. ... only about one to two percent of the bodys ... illness. Yet, surprisingly little is known about the role ... play in human health and disease. To better understand ...
... VCU Life Sciences Survey is the first poll to ... skin cells can be used to create stem cells ... of this development, more than six in 10, or ... cell research is still needed, 22 percent say this ...
... Line Utilizes World,s Best Selling Silicon ... ... Dec. 18 ,AuthenTec, Inc. (Nasdaq: AUTH ), the world,s ... Bulletin Board: BMRX), a,leading provider of biometrically secured consumer products, ...
Cached Biology News:NIH launches Human Microbiome Project 2NIH launches Human Microbiome Project 3NIH launches Human Microbiome Project 4NIH launches Human Microbiome Project 5Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows 2bioMETRX, Inc. Announces Integration of AuthenTec Fingerprint Sensor in smartTOUCH(TM) Product Line 2bioMETRX, Inc. Announces Integration of AuthenTec Fingerprint Sensor in smartTOUCH(TM) Product Line 3